The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
 
Robert Hugh Jones
Travel, Accommodations, Expenses - Merck Serono
 
Margherita Carucci
No Relationships to Disclose
 
Angela Claire Casbard
No Relationships to Disclose
 
Rachel Butler
Stock and Other Ownership Interests - AstraZeneca (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Fouad Alchami
No Relationships to Disclose
 
Catherine Jane Bale
No Relationships to Disclose
 
Pavel Bezecny
No Relationships to Disclose
 
Johnathan Joffe
No Relationships to Disclose
 
Sarah Moon
Consulting or Advisory Role - Tesaro
Travel, Accommodations, Expenses - ESMO
 
Chris Twelves
Honoraria - Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Daiichi Sankyo; Pfizer
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; MSD
 
Ramachandran Venkitaraman
No Relationships to Disclose
 
Simon Waters
Consulting or Advisory Role - Genomic Health; Novartis
Speakers' Bureau - Genomic Health; Novartis; Pfizer; Roche
 
Sacha Jon Howell
No Relationships to Disclose